BIOMARK
LIVE

Serial Number

97873713

Owner

BIOMARK CANCER SYSTEMS INC.

Attorney

Dianne M. Smith-Misemer

Filing Date

Apr 5, 2023

Add to watchlist:

No watchlists yet
View on USPTO

BIOMARK Trademark

Serial Number: 97873713

BIOMARK is a trademark filed by BIOMARK CANCER SYSTEMS INC. on April 5, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

BIOMARK CANCER SYSTEMS INC. (4 trademarks)

Richmond, British Columbia V6X2W2 , CA

Entity Type: 03

Trademark Details

Filing Date

April 5, 2023

Registration Date

Not Registered

Goods & Services

Antibody reagents for in vitro diagnostic use for medical purposes; diagnostic kits consisting of monoclonal antibodies, buffers, and reagents for in vitro diagnostic use for medical purposes; medical diagnostic antibody reagents for use in medical imaging; diagnostic kits consisting of monoclonal antibodies, buffers and reagents for specialized medical Raman spectrometry to monitor toxicity of drugs for medical purposes, for use in disease testing, for testing of bodily fluids for use in disease detection, namely, cancer, for screening the acetylated form of Amantadine in body fluids and human tissues samples, for use in the early detection of cancer by detecting and analyzing the levels of Spermine/Spermidine N-Acetyl Transferase (SSAT) in human tissue samples; medical diagnostic assays for testing bodily fluids in drug screening applications, namely, assays for determining the efficacy of anti-cancer drugs; medical diagnostic assays for testing bodily fluids that test for the presence and effects of drug candidates in the body; drug testing kits comprised of medial diagnostic reagents and assays for testing body fluids; medical diagnostic reagents and assays for the analysis of body fluids; diagnostic biomarker reagents for medical purposes

Providing an interactive web site featuring technology that enables users to enter, access, track, store, monitor, analyze and generate health and medical information and reports

Medical testing of a biological sample taken from a patient for diagnostic purposes in the field of oncology; medical testing of a biological sample taken from a patient for medical screening purposes in the field of oncology; providing medical evaluation to assess and measure response to cancer treatment; medical analysis services relating to the treatment of cancer patients to help healthcare professionals determine the effectiveness of treatments and to revise future treatments; medical diagnostic testing, monitoring and reporting services relating to disease recurrence and progression in the field of oncology; providing medical support in the monitoring of patients receiving medical treatments, namely remote monitoring of data indicative of the health or condition of an individual or group of individuals for medical diagnosis and treatment purposes, interactive medical monitoring and alert service for reminding clients of medical dosage, allergic sensitivity and prescription refills for medical treatment purposes; providing medical information to medial professionals in the form of analytical reports and risk classification or stratification in the field of oncology; providing medical information to patients and medical professionals in the form of reports in the field of oncology

Filing History

SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
May 31, 2026 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Sep 12, 2025 RCSC
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Sep 11, 2025 RCCK
REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
Mar 10, 2025 RCSC
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Feb 4, 2025 RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Feb 4, 2025 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jun 11, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Jun 11, 2024 GNSL
SUSPENSION LETTER WRITTEN
Jun 11, 2024 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 12, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 12, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Apr 12, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 12, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jan 12, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jan 12, 2024 CNRT
ASSIGNED TO EXAMINER
Jan 2, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 1, 2023 NWOS
NEW APPLICATION ENTERED
Apr 8, 2023 NWAP